PBT collapsed 72.1% on flat 0.8% revenue as below-EBITDA costs absorbed result

The damage sits below EBITDA: depreciation, interest on $2.4b of gross borrowings, and a higher tax line all expanded against a barely-changed top line.

Operating cash flow fell from $290.0m to $238.0m. Capex was cut 15.6% to $222.0m, leaving pre-lease free cash flow of $16.0m versus $27.0m. The interim dividend rose 21.4% to 17 cents per share, and FY23 EBITDA guidance was lifted to $675-690m.

PBT fell 72.1% on revenue growth of 0.8% and EBITDA down only 1.4%, so the read on the core business is materially better than the headline NPAT suggests. EBITDA margin of 70.2% sits at the upper edge of the supplied historical range (3-period mean 69.6%), which means operating economics are still tracking the recent baseline despite the bottom-line print.

The effective tax rate jumped to 47.1% from 31.1%, amplifying the NPAT decline. That 16-percentage-point step adds about 6.5 percentage points to the gap between PBT growth (-72.1%) and NPAT growth (-78.6%). The current rate also sits at the lower edge of the supplied historical range (mean 150.2%, reflecting prior-period distortions), so the rate itself is not abnormal in context, but the year-on-year step explains why NPAT looks worse than the underlying earnings.

The dividend lift sits awkwardly against cash and earnings cover. The 17c per share interim implies a payout ratio of 425.0% of NPAT (versus 155.6% prior), and pre-lease FCF of only $16.0m is well short of the dividend cost. Chorus is clearly funding distributions from the larger EBITDA base, not from reported earnings, which means the dividend story is tied to the EBITDA guidance trajectory rather than to the statutory profit line.

With HY23 EBITDA at $342.0m, the implied second-half range is $333-348m, broadly consistent with the FY22 shape in which HY22 contributed 51.4% of full-year EBITDA. The guidance lift is the cleanest forward signal in the release and supports the read that the EBITDA line is durable even where reported NPAT is not.

No revenue or NPAT guidance is supplied, and there is no commentary in the supplied excerpts that explains the size of the PBT step-down. The release does not bridge to D&A or interest movements explicitly, so the gap between the operating performance and the bottom line cannot be fully decomposed from the supplied material.

Cash conversion of 69.6% is within the supplied historical range (mean 69.4%), but it has fallen materially from the 83.6% recorded in the prior comparable, and receivable days extended by 9.4 days to 56.5. Trade debtors rose 20.8% to $151.0m on essentially flat revenue, which means a meaningful slice of reported revenue has not yet converted into cash.

The capex cut of 15.6% to $222.0m flatters pre-lease FCF, and the lower capex intensity (45.6% of revenue versus 54.5% prior) is the main reason pre-lease FCF is not worse. Leverage of 6.55x net debt to EBITDA sits below the historical baseline mean of 8.15x, providing some balance-sheet capacity, but ROE has weakened to 1.8% from 8.1% on the lower NPAT.

This briefing cannot assess the underlying interest-cost and depreciation movements behind the PBT collapse because the supplied excerpts do not bridge below the EBITDA line.